Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.

Abstract: A device 1 with at least one electrode 8 for generating an electrical field in a chamber 7 is disclosed. The device 1 comprises at least one input channel 6 for introducing a fluid into the chamber 7, and at least one output channel 11 for discharging the fluid from the chamber 7. Also disclosed is a method for stabilising the flow of a fluid through a chamber 7 in which an electrical field is generated and which has at least one input channel 6 for introducing the fluid into the chamber and at least one output channel 11 for discharging the fluid from the chamber 8. To avoid undesirable backflow of the fluid due to gas formation, the average inside diameter of the input channel 6 of device 1 is smaller than the average inside diameter of the output channel 11.

Abstract: A buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce the biologically active molecules into the cells using electric current. The buffer solution includes HEPES and at least 10 mmol*1?1 magnesium ions (Mg2+). The buffer solution has a buffer capacity of at least 20 mmol*1?1*pH?1 at a change in the pH from pH 7 to pH 8 and at a temperature of 25° C. The buffer solution also has an ionic strength of at least 200 mmol*1?1.

Abstract: A buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce said biologically active molecules into the cells using electric current. The buffer solution includes at least one of sodium succinate, mannitol and sodium lactobionate. The buffer solution has a buffer capacity of at least 20 mmol*l?1*pH?1 at a change in the pH from pH 7 to pH 8 and at a temperature of 25° C., and an ionic strength of at least 200 mmol*l?1.

Abstract: The invention relates to a buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce biologically active molecules into cells using an electric current. The inventive buffer solution has a buffering capacity of at least 20 mmol?1×pH?1 and an ionic strength of at least 200 mmol×1?1 during a change to the pH value from pH 7 to pH 8 and at a temperature of 25° C. The use of a buffer solution of this type allows biologically active molecules to be introduced into animal and human cells with a high degree of transfection efficiency and at the same time a low cell mortality. Different cell types, in particular dormant and actively dividing cells of low activity, can be successfully transfected in the buffer solution.

Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.